The people against Gilead. Activists protest at the Brazilian patent office, calling for Gilead’s last sofosbuvir patent application to be rejected
Activists gathered at the Brazilian Patent Office (INPI) in Rio de Janeiro this week, and Gilead’s office in São Paulo....
Read more about The people against Gilead. Activists protest at the Brazilian patent office, calling for Gilead’s last sofosbuvir patent application to be rejected
Collective efforts by civil society groups bar the way to Hepatitis C patents
Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position...
Read more about Collective efforts by civil society groups bar the way to Hepatitis C patents
Civil society key in TRIPS flexibility implementation
Civil society plays an instrumental role in actively defending access to affordable to medicines, making use of TRIPS flexibilities, and...
Read more about Civil society key in TRIPS flexibility implementation
Gilead’s patent application on sofosbuvir rejected in Brazil
Rejected! That was the decision issued by Brazil’s National Institute of Industrial Property (INPI) over one of Gilead’s patent applications...
Read more about Gilead’s patent application on sofosbuvir rejected in Brazil
Fixing the broken patent system: From Marrakech and back again
Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical...
Read more about Fixing the broken patent system: From Marrakech and back again
Storify: Pathways to Access #GSIPA2M
[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave
Read more about Storify: Pathways to Access #GSIPA2M
GSIPA2M: Malaysia Ministry of Health 2018 winner of the Leadership Award on Intellectual Property and Access to Medicines
Malaysia’s “historic decision” to issue a compulsory license on Hep C medicine, sofosbuvir, stands up to Big Pharma, and will mean...
Read more about GSIPA2M: Malaysia Ministry of Health 2018 winner of the Leadership Award on Intellectual Property and Access to Medicines
Argentina: Patent rejected on hepatitis C drug, sofosbuvir
A decision by the patent office in Argentina (INPI) to reject Gilead’s patent on key hepatitis C drug, sofosbuvir, is...
Read more about Argentina: Patent rejected on hepatitis C drug, sofosbuvir
São Paulo protest exposes how Gilead’s actions block access to medicines around the world
In São Paulo, on 31 October 2017, activists from around the world held a protest at the headquarters of...
Read more about São Paulo protest exposes how Gilead’s actions block access to medicines around the world
The Indonesian patent club – and its impact on Hep C treatment
Communities are refusing to accept patent abuse – challenging unmerited patents, and finding ways around them in the meantime. Community...
Read more about The Indonesian patent club – and its impact on Hep C treatment